These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37157080)

  • 21. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR
    Lehmann BD; Abramson VG; Sanders ME; Mayer EL; Haddad TC; Nanda R; Van Poznak C; Storniolo AM; Nangia JR; Gonzalez-Ericsson PI; Sanchez V; Johnson KN; Abramson RG; Chen SC; Shyr Y; Arteaga CL; Wolff AC; Pietenpol JA;
    Clin Cancer Res; 2020 May; 26(9):2111-2123. PubMed ID: 31822498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer.
    Zhu A; Li Y; Song W; Xu Y; Yang F; Zhang W; Yin Y; Guan X
    Cell Physiol Biochem; 2016; 38(3):1003-14. PubMed ID: 26938985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.
    Cuenca-López MD; Montero JC; Morales JC; Prat A; Pandiella A; Ocana A
    BMC Cancer; 2014 Apr; 14():302. PubMed ID: 24779793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of the Androgen Receptor Signaling in Breast Malignancies.
    Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M
    Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.
    Xu F; Xu K; Fan L; Li X; Liu Y; Yang F; Zhu C; Guan X
    Chin Med J (Engl); 2024 Feb; 137(3):338-349. PubMed ID: 38105538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
    Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
    Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
    McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells.
    Choupani E; Madjd Z; Saraygord-Afshari N; Kiani J; Hosseini A
    PLoS One; 2022; 17(12):e0279522. PubMed ID: 36548336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
    Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
    Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.
    Kucukzeybek BB; Bayoglu IV; Kucukzeybek Y; Yıldız Y; Oflazoglu U; Atahan MK; Taskaynatan H; Alacacioglu A; Yigit S; Tarhan MO
    Pol J Pathol; 2018; 69(2):157-168. PubMed ID: 30351863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen blockade based clinical trials landscape in triple negative breast cancer.
    Shi Y; Yang F; Huang D; Guan X
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):283-290. PubMed ID: 29807045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis.
    Wang C; Pan B; Zhu H; Zhou Y; Mao F; Lin Y; Xu Q; Sun Q
    Oncotarget; 2016 Jul; 7(29):46482-46491. PubMed ID: 27374089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review.
    Choupani E; Mahmoudi Gomari M; Zanganeh S; Nasseri S; Haji-Allahverdipoor K; Rostami N; Hernandez Y; Najafi S; Saraygord-Afshari N; Hosseini A
    Pharmacol Rev; 2023 Mar; 75(2):309-327. PubMed ID: 36781219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new?
    Elsers DA; Masoud EM; Kamel NAMH; Ahmed AM
    Ann Diagn Pathol; 2021 Dec; 55():151831. PubMed ID: 34634762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.